Quest Diagnostics (DGX) SVP gets stock award and sells shares under 10b5-1 plan

Rhea-AI Filing Summary

Quest Diagnostics senior vice president for Diagnostic Services Patrick Plewman reported a mix of stock award activity, tax-related share disposition, and an open-market sale of common stock. On March 4, he acquired 5,682 shares as a grant or award at $204.86 per share, issued in settlement of a performance stock award approved under Rule 16b-3(d). On the same date, 2,827 shares were disposed of at $204.86 per share to Quest Diagnostics to cover tax withholding obligations from that award, leaving 18,053 shares directly owned afterward. On March 5, he sold 2,855 shares of common stock in an open-market transaction at $206.21 per share under a pre-arranged Rule 10b5-1 trading plan, resulting in direct ownership of 15,198 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plewman Patrick

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP for Diagnostic Services

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		5,682(1)	A	$204.86	20,880	D
Common Stock	03/04/2026		F		2,827(2)	D	$204.86	18,053	D
Common Stock	03/05/2026		S(3)		2,855	D	$206.21	15,198	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d).

2. Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award.

3. This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Remarks:

	Sean D. Mersten, Attorney in Fact for Patrick Plewman	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Quest Diagnostics (DGX) report for Patrick Plewman?

Quest Diagnostics reported that executive Patrick Plewman received a stock award of 5,682 common shares, disposed of 2,827 shares to cover tax withholding, and sold 2,855 shares in an open-market transaction. These transactions adjusted his directly owned stake to 15,198 shares.

How many Quest Diagnostics (DGX) shares did Patrick Plewman sell in the open market?

Patrick Plewman sold 2,855 shares of Quest Diagnostics common stock in an open-market transaction at $206.21 per share. This sale was executed on March 5 under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.

What stock award did Patrick Plewman receive from Quest Diagnostics (DGX)?

Patrick Plewman received 5,682 shares of Quest Diagnostics common stock issued in settlement of a performance stock award. The award was approved in accordance with Rule 16b-3(d), and the shares were valued at $204.86 per share on the grant date.

Why did Patrick Plewman dispose of some Quest Diagnostics (DGX) shares on March 4?

Patrick Plewman disposed of 2,827 Quest Diagnostics common shares back to the issuer solely to cover tax withholding obligations. These obligations arose from settlement of his performance stock award that delivered 5,682 shares on March 4 at $204.86 per share.

How many Quest Diagnostics (DGX) shares does Patrick Plewman own after these transactions?

After the March 4 tax-withholding disposition and the March 5 open-market sale, Patrick Plewman directly owns 15,198 shares of Quest Diagnostics common stock. This reflects his updated ownership following the stock award, tax-related share delivery, and subsequent sale.

Were Patrick Plewman’s Quest Diagnostics (DGX) share sales pre-planned?

Yes. The filing states that the 2,855-share open-market sale on March 5 was effected under a Rule 10b5-1 sales plan. Such plans allow insiders to pre-schedule trades, providing structure and reducing concerns about trade timing decisions.